Suited for unknown reasons a protein called amyloid beta aggregates into toxic plaques in the brain, slaying neurons. These plaques are one of the hallmarks of Alzheimer’s disease. Now two remodelled animal studies show an eye to the first time that the deadly transformation of amyloid beta into plaques can be prevented through an interaction between amyloid beta and another protein called cystatin C.

Although much work needs to be done, these advanced findings may open the door to new treatments for Alzheimer’s disease that mimic the effects of cystatin C, says Efrat Levy, Ph.D., Associate Professor in the Departments of Psychiatry and Pharmacology at New York University School of Nostrum, and the lead author of the scrutinize. “We are in actuality excited by these findings because recent studies show that cystatin C is protective against a difference of insults that cause cell death in the brain. Our potential therapeutic approach focuses on keeping amyloid beta in a not wash lavishly soluble form, preventing its hoard in the brain, and thus slowing, halting, or reversing disease progression,” says Dr. Levy, who is also Mr Big of the Laboratory of Molecular Pathology of Cerebral Amyloidosis at the Nathan S. Kline Institute exchange for Psychiatric Probing in Orangeburg, New York.

With be supportive of from the Alzheimer’s Association, Dr. Levy’s laboratory has already begun studies to develop a drug that resolution mimic the ability of cystatin C to bind to a non-pathological framework of amyloid beta and thereby prevent its accumulation into plaques in the brain.

Alzheimer’s is estimated to affect 5 million Americans and there are no medicines that can lacuna or control the disease. Many laboratories worldwide are pursuing ways to prevent the clumping of amyloid beta as viable therapies for the disease. It isn’t known whether the protein actually causes Alzheimer’s, but amyloid beta is one of the proteins implicated in the disease organize.

The two studies appear in the on-line November 18, 2007, edition of the periodical Scenery Genetics and will be published in its December 2007 issue.

The beforehand study was performed by Dr. Levy in collaboration with other investigators at the Nathan S. Kline Institute for Psychiatric Research and New York University School of Medicine. The second study was performed by Dr. Levy and colleagues in the laboratory of Dr. Mathias Jucker at the Hertie-Institute for Clinical Percipience Research in Tubingen, Germany.

Both studies occupied mice that were genetically engineered to introduce kind-hearted cystatin C as well as abundant amounts of amyloid beta plaques in their brains. The cystatin C bound to the soluble, non-pathological form of amyloid beta in these mice and inhibited the aggregation and deposition of amyloid beta plaques in the brain.

The research shows that cystatin C binds soluble amyloid beta also in the human brain, and suggests that this binding inhibits its aggregation into insoluble plaques in humans, says Dr. Levy. Cystatin C in Britain artistry and confederation fluid levels vary among healthy individuals and can be influenced by certain hormones, aging, and invariable pathological conditions, she says. Furthermore, it was recently demonstrated that a genetic variation in the cystatin C gene in hominoid populations is linked to a greater risk of developing Alzheimer’s malady during aging.

These findings suggest, says Dr .Levy, that indeed clever modifications of cystatin C protein levels could affect amyloid beta accumulation and deposition in the intellectual, thereby modifying disease progression.

Cystatin C is set up in all masses fluids and tissues of mammals. It is a jack-of-all-trades, playing a unshaded task in tons functions, including cell proliferation and growth, modulation of the inflammatory response, and bone resorption. The protein also has been implicated in neuronal degeneration and repair of the on tenterhooks system.

“The work of Dr. Levy and colleagues offers foremost insights into how cystatin C may reduce the risk for Alzheimer’s disease, setting the stage to go to a new approach to therapy,” said Ralph A. Nixon, M.D., Ph.D., Professor of Psychiatry and Apartment Biology at NYU School of Physic and Steersman of the Center for Dementia Research at the Nathan S. Kline Organization. Dr. Nixon also directs the Silberstein Initiate at NYU School of Remedy.

“Given the increasing primacy of this complaint, its staggering social and economic costs in spite of patients and their families, and the limitations of existing therapies, we are very hopeful that this experiment with will-power lead to improved medications to prevent the disease and frustrate its captivating symptoms,” said Dr. Harold S. Koplewicz, Pilot of the Nathan S. Kline Institute, and the Chair of the Department of Young man and Youthful Psychiatry and a Infirmity-Dean at NYU Followers of Medicine.

—————————-
Article adapted by Medical News Today from original press release.
—————————-

Source:
Pam McDonnell
New York University Medical Center and School of Panacea